Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics is participating in the ACMG Annual Clinical Genetics Meeting from March 23–26, 2022, showcasing its complete product portfolio for the first time. Attendees will include combined teams exhibiting Optical Genome Mapping Solutions, Testing Services, and Software. Six scientific posters will discuss advancements in clinical genetics research, particularly for rare undiagnosed genetic diseases. Bionano aims to support genetic clinicians and researchers with enhanced solutions, promoting discovery and improving diagnostics for patients with genetic disorders.

Bionano Genomics (BNGO) announced the validation of its optical genome mapping (OGM) technology in detecting structural variants (SVs) in hematological neoplasms. The study, involving 59 samples, showed OGM's 98.7% sensitivity and 100% specificity, outperforming traditional methods like karyotyping and FISH. OGM also detected additional chromosomal aberrations in cases where traditional methods failed. Researchers suggested OGM as a potential first-tier test in clinical settings, enhancing the identification of new therapeutic targets. The study reflects increasing evidence for OGM's efficacy in routine use.

Bionano Genomics (BNGO) announced that its management will present virtually at the 32nd Annual Oppenheimer Healthcare Conference. CEO Erik Holmlin is scheduled to deliver a corporate overview on March 15, 2022, at 5:40 am PT/8:40 am ET. The presentation will be accessible on Bionano’s Investors section on their website. The company specializes in optical genome mapping and offers software solutions for genomic data visualization and interpretation, aiming to revolutionize genome analysis in research and diagnostics.

Bionano Genomics (BNGO) announced the appointment of Dr. Aleks Rajkovic to its board of directors. Dr. Rajkovic, currently the Chief Genomics Officer at UCSF, brings extensive expertise in genomic medicine, including reproductive health and genetic screening. His appointment aims to enhance Bionano's efforts in expanding the capabilities of optical genome mapping (OGM) and its applications in clinical research and patient management. The company continues to focus on revolutionizing genomic analysis with its Saphyr® system and related software solutions.

Bionano Genomics (BNGO) announced that CEO Erik Holmlin will present at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 11:10 AM PT/2:10 PM ET. The presentation will provide a corporate overview and can be viewed on the company's website. Bionano is known for its optical genome mapping solutions and the N_xClinical™ software, aimed at enhancing genomic data analysis and reporting. The company's mission is to transform genome analysis in clinical research, particularly in understanding genetic conditions.

Bionano Genomics reported a remarkable 111% revenue growth for full-year 2021, totaling $18.0 million, with a 58% increase to $6.3 million in Q4. The company boasts a robust balance sheet with $250.6 million in cash as of December 31, 2021. Bionano aims for 2022 revenue between $24 million and $27 million, showcasing potential growth of 33% to 50%. Significant advancements include expanding their Saphyr system installations by 69% and enhancing software capabilities through the acquisition of BioDiscovery.

Bionano Genomics (Nasdaq: BNGO) has launched a strategic initiative focused on rare undiagnosed genetic diseases (RUGD) in recognition of Rare Disease Day. Currently, over 350 million people globally are affected by rare diseases, with about 80% attributed to genetic factors. Despite advancements in genetic testing methods, more than 50% of patients remain undiagnosed. Bionano’s initiative includes support for research, educational awareness, and a three-year financial commitment to the ACMG Foundation to expand the genetic workforce. This effort aims to enhance patient care and improve diagnosis rates for rare diseases.

Bionano Genomics (BNGO) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its fourth quarter and year-end 2021 financial results and share recent corporate developments. The call can be accessed via toll-free and international dial-ins, with a conference ID of 8795841. An archived version of the webcast will be available in the Investors section of the company's website. Bionano focuses on genome analysis, providing solutions and diagnostic services for biology and medicine.

Bionano Genomics announced a peer-reviewed study showcasing its Optical Genome Mapping (OGM) as a superior method for analyzing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The research, published in the International Journal of Cancer, found that OGM detected 31% more European Leukemia Net abnormalities and 35% more cases than traditional methods like karyotyping and FISH. Moreover, OGM's cost-effectiveness was highlighted, equating to two FISH probes.

CEO Erik Holmlin emphasized OGM's potential in routine diagnostics, aiming for improved clinical outcomes.